Preview

Rational Pharmacotherapy in Cardiology

Advanced search

GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES

https://doi.org/10.20996/1819-6446-2007-3-5-88-111

Full Text:

Abstract

The Task Force on Diabetes and Cardiovascular diseases of the European Society of Cardiology and of the European Association for the Study of Diabetes.

About the Authors

L. Ryden

Russian Federation


E. Standl

Russian Federation


M. Bartnik

Russian Federation


G. Van den Berghe

Russian Federation


J. Betteridge

Russian Federation


M.J. de Boer

Russian Federation


F. Cosentino

Russian Federation


B. Jonsson

Russian Federation


M. Laakso

Russian Federation


K. Malmberg

Russian Federation


S. Priori

Russian Federation


J. Ostergren

Russian Federation


J. Tuomilehto

Russian Federation


I. Thrainsdottir

Russian Federation


References

1. (источники литературы NN 1-382 см. РФК 2007;4:91-99)

2. The Hypertension Detection and Follow-up Programme Cooperative Research Group. Mortality findings for stepped-care and referred-care participants in the hypertension detection and follow-up programme, stratified by other risk factors. Prev Med 1985; 14: 312–335.

3. Lindholm LH, Hansson L, Ekbom T et al. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 2000;18:1671–1675.

4. Hansson L, Hedner T, Lund-Johanson P et al. Randomized trial of effects of calcium-antagonists compared with diuretics and (blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) Study. Lancet 2000;356:359–365.

5. Mancia G, Brown M, Castaigne A et al. Outcomes with nifedipine GITS or CoAmizolide in hypertensive diabetics and nondiabetics in intervention as a goal in hypertension (INSIGHT). Hypertension. 2003;41:431–436.

6. Dahlo¨f B, Sever P, Poulter N et al. The enhanced prevention of cardiovascular events with an amlodipine-based regimen compared with an atenolol-based regimen. The Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm (ASCOT—BPLA): a multicentre randomized controlled trial. Lancet 2005;366: 895–906.

7. Norhammar A, Malmberg K, Ryden L, Tornvall P, Stenestrand U, Wallentin L; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA). Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction. Eur Heart J 2003;24:838–844.

8. Franklin K, Goldberg RJ, Spencer F, Klein W, Budaj A, Brieger D, Marre M, Steg PG, Gowda N, Gore JM; GRACE Investigators. Implications of diabetes in patients with acute coronary syndromes. The Global Registry of Acute Coro￾nary Events. Arch Intern Med 2004; 164:1457–1463.

9. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E, Fioretti PM, Simoons ML, Battler A. A prospective survey on the characteristic, treatments and outcomes of patients with acute coronary syndromes in Europe and Mediterranean basin. The Euro Heart Survey of Acute Coronary Syndromes. Eur Heart J 2002;23: 1190–1201.

10. Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000;102: 1014–1019.

11. Norhammar A, Tenerz A, Nilsson G, Hamsten A, Efendic S, Ryde´n L, Malmberg K. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140–2144.

12. Bartnik M, Malmberg K, Hamsten A, Efendic S, Norhammar A, Silveira A, Tenerz A, Ohrvik J, Ryde´n L. Abnormal glucose tolerance—a common risk factor in patients with acute myocardial infarction in comparison with population-based controls. J Intern Med 2004;256:288–297.

13. Pyo¨ra¨la¨ K, Lehto S, De Bacquer D et al. on behalf of the EUROASPIRE I and II Group. Risk factor management in diabetic and non-diabetic coronary heart disease patients. Findings from heart disease patients from EUROASPIRE I and II surveys. Diabetologia 2004;47: 1257–1265.

14. Bartnik M, Ryde´n L, Ferrari R, Malmberg K, Pyo¨ra¨la¨ K, Simoons ML, Standl E, Soler-Soler J, O¨ hrvik J, on behalf of the Euro Heart Survey Investigators. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. Eur Heart J 2004;25: 1880–1890.

15. Bartnik M. Studies on prevalence, recognition and prognostic implications. Glucose regulation and coronary artery disease. Karolinska Institutet, Stockholm 2005 (ISBN:91-7140-401-5).

16. Lo¨wel H, Koenig W, Engel S, Ho¨rmann A, Keil U. The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 2000;43: 218–226.

17. van Domburg RT, van Miltenburg-van Zijl AJ, Veerhoek RJ, Simoons ML. Unstable angina: good long-term outcome after a complicated early course. J Am Coll Cardiol 1998;31:1534–1539.

18. Mukamal KJ, Nesto RW, Cohen MC, Nuller JE, Maclure M, Sherwood JB, Mittleman MA. Impact of diabetes on long-term survival after acute myocardial infarction. Comparability of risk with prior myocardial infarction. Diabetes Care 2001;24:1422–1427.

19. Timmer JR, van der Horst IC, de Luca G, Ottervanger JP, Hoorntje JC, de Boer MJ, Suryapranata H, Dambrink JH, Gosselink M, Zijlstra F, van ’t Hof AW; Zwolle Myocardial Infarction Study Group. Comparison of myocardial perfusion after successful primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction with versus without diabetes mellitus. Am J Cardiol 2005;95:1375–1377.

20. Svensson AM, Abrahamsson P, McGuire DK, Dellborg M. Influence of diabetes on long-term outcome among unselected patients with acute coronary events. Scand Cardiovasc J 2004;38:229–234.

21. Mak KH, Moliterno DJ, Granger CB, Miller DP, White HD, Wilcox RG, Califf RM, Topol EJ, for the GUSTO-I Investigators. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997;30:171–179.

22. McGuire DK, Emanuelsson H, Granger CB, Magnus Ohman E, Moliterno DJ, White HD, Ardissino D, Box JW, Califf RM, Topol EJ. Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb Study. GUSTO IIb Investigators. Eur Heart J 2000;21:1750–1758.

23. Gitt AK, Schiele R, Wienbergen H, Zeymer U, Schneider S, Gottwik MG, Senges J; MITRA Study. Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. Acta Diabetol 2003;40(Suppl. 2):S343–S347.

24. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, Wallentin L. Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 2004;43:585–591.

25. Aguilar D, Solomon SD, Kober L, Rouleau JL, Skali H, McMurray JJ, Francis GS, Henis M, O’Connor CM, Diaz R, Belenkov YN, Varshavsky S, Leimberger JD, Velazquez EJ, Califf RM, Pfeffer MA. Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. Circulation 2004;21:1572–1578.

26. Marchioli R, Avanzini F, Barzi F, Chieffo C et al. on behalf of GISSIPrevenzione Investigators. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations. GISSI-Prevenzione mortality chart. Eur Heart J 2001;22: 2085–2103.

27. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 2004; 24:816–823.

28. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997; 314:1512–1515.

29. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997;96:1152–1156.

30. Diaz R, Paolasso EA, Piegas LS et al. on behalf of the ECLA Collaborative Group. Metabolic modulation of acute myocardial infarction. The ECLA Glucose-Insulin-Potassium Pilot Trial. Circulation 1998;98: 2227–2234.

31. Mehta SR, Eikelboom JW, Demers C, Maggioni AP, Commerford PJ, Yusuf S. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. Can J Physiol Pharmacol 2005;83:98–103.

32. O’Connor MC, Hathaway WR, Bates ER, Leimberger JD, Sigmon KN, Kereiakes DJ, George BS, Samaha JK, Abbottsmith CW, Candela RJ, Topol EJ, Califf RM. Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. Am Heart J 1997;133: 663–673.

33. Lewis EF, Moye LA, Rouleau JL, Sacks FM, Arnold JM, Warnica JW et al. Predictors of late development of heart failure in stable survivors of myocardial infarction. The CARE Study. J Am Coll Cardiol 2004; 42: 1446–1453.

34. Valeur N, Clemmensen P, Saunamaki K, Grande P, for the DANAMI-2 Investigators. The prognostic value of pre-discharge exercise testing after myocar￾dial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. Eur Heart J 2005;26:119–127.

35. Campbell RWF, Wallentin L, Verheugt FWA, Turpie AGG, Maseri A, Klein W, Cleland JGF, Bode C, Becker R, Anderson J, Bertrand ME, Conti CR. Management strategies for a better outcome in unstable coronary artery disease. Clin Cardiol 1998;21:314–322.

36. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KAA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FVA, Wijns W; Task Force of the ESC. Acute coronary syndromes acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003; 24: 28–66.

37. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W; Task Force of the ESC. Acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809–1840.

38. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Cats VM, OrthGome´r K, Perk J, Pyo¨ra¨la¨ K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D et al; Third Joint Task Force of the European and other Societies. European Guidelines on Cardiovascular Disease Prevention. Eur J Cardiovasc Preven Rehab 2003; 10(Suppl. 1):S1–S78.

39. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med 1999;16:716–730. http://www. staff.ncl.ac. uk/Philip.home/guidelines.

40. International Diabetes Association 2005—Clinical Guidelines Task Force— Global Guidelines for type 2 Diabetes. http://www. idf.org/webdata/ docs/IDF%20GGT2D.pdf.

41. Fibrinolytic Therapy Trialists (FFT) Collaborative Group. Indication for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results form all randomized trials of more than 1000 patients. Lancet 1994; 343:311–322.

42. Mehta SR, Cannon CP, Fox KAA, Wallentin L, Boden WE, Spacek R, Widimsky P, McCullough PA, Braunwald E, Yusuf S. Routive vs selective invasive strategies in patients with acute coronary syndromes. JAMA 2005;293: 2908–2917.

43. Stenestrand U, Wallentin L. Early revascularisation and 1-year survival in 14- day survivors of acute myocardial infarction: a prospective cohort study. Lancet 2002;359:1805–1811.

44. Lagerqvist B, Husted S, Kontny F, Na¨slund U, Sta°hle E, Swahn E, Wallentin L and the FRISC-II Investigators. A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease. JACC 2002;40:1902–1914.

45. Freemantle N, Cleland J, Young P et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ 1999;318: 1730–1737.

46. Malmberg K, Herlitz J, Hjalmarson A° , Ryde´n L. Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infraction. Retrospective data from two large scale studies. Eur Heart J 1989; 10: 423–428.

47. Kjekshus J, Gilpin E, Blackey AR, Henning H, Ross J. Diabetic patients and beta-blockers after acute myocardial infarction. Eur Heart J 1990;11:43–50.

48. Jonas M, Reichel-Reiss H, Boyko V, Shotan A et al. for the Bezafibrate Infarction Prevention (BIP) Study Group. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273–1277.

49. Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wedel H. Mortality prediction in diabetic patients with myocardial infarction: experiences from the DIGAMI study. Cardiovasc Res 1997; 34:248–253.

50. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489–497.

51. Haas SJ, Vos T, Gilbert RE, Krum H. Are b-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 2003;146:848–853.

52. Lo´pez-Sendo´n J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C; Task Force on Beta-Blockers of the ESC. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 2004;25: 1341–1362.

53. Gheorghiade M, Goldsten S. b-blockers in the post-myocardial infarction patient. Circulation 2002;106:394–398.

54. Held PYS, Furberg CD. Calcium channel blockers in acute myocardial infarction and unstable angina: an overview. BMJ 1989;299: 1187–1892.

55. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial in￾farction and stroke in high risk patients. BMJ 2002; 324: 71–85.

56. Yusuf S, Zhao F, Mehta SR et al, The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial (CURE) Investigators. The effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494–502.

57. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90:625–628.

58. Patrono CP, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, Fitzgerald D et al. Expert consensus document on the use of antiplatelet agents. Eur Heart J 2004;25:166–181.

59. Hirsh J, Bhatt DL. Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies. Arch Intern Med 2004;164:2106–2610.

60. Zuanetti G, Latini R, Maggioni AP et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997;96: 4239–4245.

61. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782–788.

62. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML; EUROPA Investigators. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005; 26:1369–1378.

63. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D, Paolasso E, Ahmed R, Xie C, Kazmi K, Tai J, Orlandini A, Pogue J, Liu L; CREATE-ECLA Trial Group Investigators. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA ran￾domized controlled trial. The CREATEECLA trial group investigators. JAMA 2005;293: 437–446.

64. Van den Berghe G, Wouters PJ, Weekers F et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345: 1359–1367.

65. Wallner S, Watzinger N, Lindschinger M et al. Effects of intensified life style modification on the need for further revascularization after coronary angioplasty. Eur J Clin Invest 1999;29:372–379.

66. Favaloro RG, Effler DB, Groves LK, Sones FM, Fergusson DJ. Myocardial revas￾cularization by internal mammary artery implant procedures. Clinical experience. J Thorac Cardiovasc Surg 1967;54: 359–370.

67. Sheldon WC, Favaloro RG, Sones FM, Effler DB. Reconstructive coronary artery surgery. Venous autograft technique. JAMA 1970;213: 78–82.

68. Gruentzig A, Hirzel H, Goebel N et al. Percutaneous transluminal dilatation of chronic coronary stenoses. First experiences. Schweiz Med Wochenschr 1978;108:1721–1723.

69. Barsness GW, Peterson ED, Ohman EM et al. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation 1997;96:2551–2556.

70. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider SH. Diabetes mellitus increases short-term mortality and morbidity in patients undergoing coronary artery bypass graft surgery. J Am Coll Cardiol 2002;40:418–423.

71. Thourani VH, Weintraub WS, Stein B et al. Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. Ann Thorac Surg 1999;67:1045–1052.

72. Stein B, Weintraub WS, Gebhart SP et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation 1995;91:979–989.

73. Van Belle E, Ketelers R, Bauters C et al. Patency of percutaneous transluminal coronary angioplasty sites at 6-month angiographic follow-up: a key determinant of survival in diabetics after coronary balloon angioplasty. Circulation 2001;103:1218–1224.

74. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW. Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1996;94:1818–1825.

75. Laskey WK, Selzer F, Vlachos HA et al., for the Dynamic Registry. Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). Am J Cardiol 2002;90:1062–1067.

76. Mehran R, Dangas GD, Kobayashi Y et al. Short- and long-term results after multivessel stenting in diabetic patients. J Am Coll Cardiol 2004;43: 1348–1354.

77. The BARI Investigators. Seven-year outcome in the bypass angioplasty revascularization investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122–1129.

78. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multives￾sel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761–1769.

79. Detre KM, Guo P, Holubkov R et al. Coronary revascularization in diabetic patients. A comparison of the randomized and observational components of the bypass angioplasty revascularization investigation (BARI). Circulation 1999;99:633–640.

80. Mathew V, Frye RL, Lennon R, Barsness GW, Holmes DR. Comparison of survival after successful percutaneous coronary intervention of patients with diabetes mellitus receiving insulin versus those receiving only diet and/or oral hypoglycaemic agents. Am J Cardiol 2004;93:399–403.

81. Ong ATL, Aoki J, van Mieghem CAG et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxeleluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358–362.

82. Kouchoukos NT, Wareing TH, Murphy SF, Pelate C, Marshall WG. Risks of bi￾lateral internal mammary artery bypass grafting. Ann Thorac Surg 1990;49:210–217.

83. Milano CA, Kesler K, Archibald N, Sexton DJ, Jones RH. Mediastinitis after coronary artery bypass graft surgery: risk factors and long-term survival. Circulation 1995;92:2245–2251.

84. Magee MJ, Dewey TM, Acuff T et al. Influence of diabetes on mortality and morbidity: off-pump coronary artery bypass grafting versus coronary artery bypass grafting with cardiopulmonary bypass. Ann Thorac Surg 2001;72: 776–781.

85. Bucerius J, Gummert JF, Walther T et al. Impact of diabetes mellitus on cardiac surgery outcome. Thorac Cardiovasc Surg 2003;51: 11–16.

86. Tang GH, Maganti M, Weisel RD, Borger MA. Prevention and management of deep sternal wound infection. Semin Thorac Cardiovasc Surg 2004; 16:62–69.

87. Elezi S, Katrati A, Pache J et al. Diabetes and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998;32: 1866–1873.

88. Marso SP, Giorgi LV, Johnson WL et al. Diabetes mellitus is associated with a shift in the temporal risk profile of inhospital death after percutaneous coronary intervention: an analysis of 25,223 patients over 20 years. Am Heart J 2003;145:270–277.

89. The Bypass Angioplasty Revascularisation Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335: 217–225 [Erratum in: N Engl J Med 1997;336:147].

90. Kurbaan AS, Bowker TJ, Ilsley CD, Sigwart U, Rickards AF, the CABRI Investigators. Difference in the mortality of the CABRI diabetic and nondiabetic populations and its relation to coronary artery disease and the revascularization mode. Am J Cardiol 2001;87:947–950.

91. Zhao XQ, Brown BG, Stewart DK et al. Effectiveness of revascularization in the Emory angioplasty versus surgery trial. A randomized comparison of coro￾nary angioplasty with bypass surgery. Circulation 1996; 93:1954–1962.

92. Henderson RA, Pocock SJ, Sharp SJ, Nanchahal K, Sculpher MJ, Buxton MJ, Hampton JR. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomized in￾tervention treatment of angina. Lancet 1998;352: 1419–1425.

93. Abizaid A, Costa MA, Centemero M et al., the ARTS Investigators. Clinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients. Insights from the Arterial Revascu￾larization Therapy Study. Circulation 2001;104:533–538.

94. Rodriguez A, Bernardi V, Navia J et al., for the ERACI II Investigators. Argentine randomized study: coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple-vessel disease (ERACI II): 30-day and one-year follow-up results. J Am Coll Cardiol 2001;37:51–58.

95. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coro￾nary artery disease (the Stent or Surgery Trial): a randomized controlled trial. Lancet 2002;360:965–970.

96. Sedlis SP, Morrison DA, Lorin JD et al., Investigators of the Department of Veterans Affairs Cooperative Study No.385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. J Am Coll Cardiol 2002;40:1555–1566.

97. O’Neill WW. Multivessel balloon angioplasty should be abandoned in diabetic patients! J Am Coll Cardiol 1998;31:20–22.

98. Niles NW, McGrath PD, Malenka D et al., Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001;37:1008–1015.

99. Sabate M, Jimenez-Quevedo P, Angiolillo DJ et al., DIABETES Investigators. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175–2183.

100. Finn AV, Palacios IF, Kastrati A, Gold HK. Drug-eluting stents for diabetes mellitus. A rush to judgment? J Am Coll Cardiol 2005;45: 479–483.

101. Bhatt DL, Marso SP, Lincoff AM, Wolski KE, Ellis SG, Topol EJ. Abciximab reduces mortality in diabetics following percutaneous intervention. J Am Coll Cardiol 2000;35:922–928.

102. Scheen AJ, Warzee F, Legrand VMG. Drug-eluting stents: a meta-analysis in diabetic patients. Eur Heart J 2004;25:2167–2168.

103. Eefting F, Nathoe H, van Dijk D et al. Randomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. Circulation 2003;108:2870–2876.

104. Hannan EL, Racz MJ, Walford G, Jones RH, Ryan TJ, Bennett E, Culliford AT, Isom OW, Gold JP, Rose EA. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352: 2174–2183.

105. Gersh BJ, Frye RL. Methods of coronary revascularization—things may not be as they seem. N Engl J Med 2005;352:2235–2237.

106. Marso SP, Ellis SG, Tuzcu EM et al. The importance of proteinuria as a determinant of mortality following percutaneous coronary revascularisation in di￾abetics. J Am Coll Cardiol 1999;33:1269–1277.

107. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM. Coronary bypass graft patency in patients with diabetes in the bypass angioplasty revascularization investigation (BARI). Circulation 2002;106:2652–2658.

108. Marso SP. Optimizing the diabetic formulary: beyond aspirin and insulin. J Am Coll Cardiol 2002;40;652–661.

109. Breeman A, Hordijk M, Lenzen M et al. Treatment decisions in stable coronary artery disease in a broad range of European practices. Insights from the Euro Heart Survey on coronary revascularization. J Thor Cardiovasc Surg 2006;132:1001–1009.

110. Gibbons RJ, Abrams J, Chatterjee K et al., American College of Cardiology; American Heart Association task force on practice guidelines. Committee on the management of patients with chronic stable angina. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina— summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). Circulation 2003;107: 149–158.

111. van Bergen PF, DeckersJW, Jonker JJ, van Domburg RT, Azar AJ, Hofman A. Efficacy of long-term anticoagulant treatment in subgroups of patients after myocardial infarction. Br Heart J 1995;74: 117–121.

112. Quinn MJ, Moliterno DJ. Diabetes and percutaneous intervention: the sweet smell of success? Am Heart J 2003;145:203–205.

113. Roffi M, Topol EJ. Percutaneous intervention in diabetic patients with non-ST￾segment elevation acute coronary syndromes. Eur Heart J2004;25:190–198.

114. Angeja BG, de Lemos J, Murphy SA et al., TIMI Study Group. Impact of diabetes mellitus on epicardial and microvascular flow after fibrinolytic therapy. Am Heart J 2002;144:649–656.

115. O’Neill WW, de Boer MJ, Gibbons RJ et al. Lessons from the pooled outcome of the PAMI, Zwolle and Mayo clinic randomized trials of primary angioplasty versus thrombolytic therapy of acute myocardial infarction. J Invasive Cardiol 1998;10:4–10.

116. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ, PCAT Collaborators. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47–57.

117. Zijlstra F, Hoorntje JC, de Boer MJ et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1999;341:1413–1419.

118. Goraya TY, Leibson CL, Palumbo PJ et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol 2002;40: 946–953.

119. Van Belle E, Abolmaali K, Bauters C, McFadden EP, Lablanche J-M, Bertrand ME. Restenosis, late vessel occlusion and left ventricular function six months after balloon angioplasty in diabetic patients. J Am Coll Cardiol 1999;34:476–485.

120. Malmberg K, Ryde´n L. Myocardial infarction in patients with diabetes mellitus. Eur Heart J 1988;9:259–264.

121. Hsu LF, Mak KH, Lau KW et al. Clinical outcomes of patients with diabetes mellitus and acute myocardial infarction treated with primary angioplasty or fibrinolysis. Heart 2002;88:260–265.

122. Thomas K, Ottervanger JP, de Boer MJ, Suryapranata H, Hoorntje JC, Zijlstra F. Primary angioplasty compared with thrombolysis in acute myocardial infarction in diabetic patients. Diabetes Care 1999; 22:647–649.

123. National Heart, Lung, and Blood Institute (NHLBI). Comparison of two treatments for multivessel coronary artery disease in individuals with diabetes (FREEDOM). http://www.clinicaltrials.gov/ct/show/ NCT00086450.

124. Kapur A, Malik IS, Bagger JP et al. The Coronary Artery Revascularisation in Diabetes (CARDia) trial: background, aims, and design. Am Heart J 2005;149: 13–19.

125. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, Remme WJ; Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115–1149.

126. von Bibra, Thrainsdottir IS, Hansen A, Dounis V, Malmberg K, Ryde´n L. Tissue Doppler imaging for the detection and quantification of myocardial dysfunc￾tion in patients with type 2 diabetes mellitus. Diabetes Vasc Dis Res 2005;2:24–30.

127. Epshteyn V, Morrison K, Krishnaswamy P et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081–2087.

128. Zannad F, Briancon S, Juilliere Y et al., the EPICAL Investigators. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL study. J Am Coll Cardiol 1999; 33:734–742.

129. Kristiansson K, Sigfusson N, Sigvaldason H, Thorgeirsson G. Glucose tolerance and blood pressure in a population-based cohort study of males and females: the Reykjavik Study. J Hypertens 1995;13: 581–586.

130. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study. N Engl J Med 1971;285: 1441–1446.

131. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 2004;27: 1879–1884.

132. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women. NHANES I Epidemiologic follow-up study. Arch Intern Med 2001;161: 996–1002.

133. Wilhelmsen L, Rosengren A, Eriksson H, Lappas G. Heart failure in the general population of men—morbidity, risk factors and prognosis. J Intern Med 2001;249:253–261.

134. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A et al. Prevalence of heart failure and left ventricular dysfunction in the general population. The Rotterdam Study. Eur Heart J 1999;20:447–455.

135. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malm￾berg K et al. The association between glucose abnormalities and heart failure in the population based Reykjavı´k Study. Diabetes Care 2005;28:612–616.

136. Johansson S, Wallander MA, Ruigo´mez A, Garcia Rodrı´guez LA. Incidence of newly diagnosed heart failure in UK general practice. Eur J Heart Fail 2001;3:225–231.

137. Remes J, Reunanen A, Aromaa A, Pyo¨rala K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992;13: 588–593.

138. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29–34.

139. Amato L, Paolisso G, Cacciatore F et al. on behalf of the Osservatorio Geriatrico Regione Campania Group. Congestive heart failure predicts the devel￾opment of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Med 1997;23:213–218.

140. Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A et al. The prognosis of heart failure in the general population. The Rotterdam Study. Eur Heart J 2001;22:1318–1327.

141. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J 2004;25:656–662.

142. Thrainsdottir IS, Aspelund T, Hardarson T, Malmberg K, Sigurdsson G, Thorgeirsson G, Gudnason V, Ryde´n L. Glucose abnormalities and heart fail￾ure predict poor prognosis in the population based Reykjavı´k Study. Eur J Car￾diovasc Prev Rehabil 2005;12:465–471.

143. Solang L, Malmberg K, Ryde´n L. Diabetes mellitus and congestive heart failure. Eur Heart J 1999;20:789–795.

144. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342:821–828.

145. Konstam MA, Rousseau MF, KronenbergMW, Udelson JE, Melin J, Stewart D et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators. Circulation 1992;86:431–438.

146. Konstam MA, Patten RD, Thomas I, Ramahi T, La Bresh K, Goldman S et al. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: results of the ELITE ventricular function substudy. Am Heart J 2000;139:1081–1087.

147. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–1435.

148. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. on behalf of the ELITE II Investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial—the Losartan Heart Failure Survival Study ELITE-II. Lancet 2000;355:1582–1587.

149. The SOLVD Investigators. Effect of enalapril on survival in patients with re￾duced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991;325:293–302.

150. Ryde´n L, Armstrong PW, Cleland JG et al. Efficacy and safety of highdose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. Eur Heart J 2000;21:1967–1978.

151. Pfeffer M, Braunwald E, Moye´ et al. on behalf of the SAVE investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669–677.

152. Moye´ LA, Pfeffer MA, Wun CC et al. Uniformity of captopril benefit in the SAVE study: subgroup analysis. Survival and ventricular enlargement study. Eur Heart J 1994;15(Suppl. B):2–8.

153. Herings RMC, deBoer A, Stricker BHC, Leufkens HGM, Porsius A. Hypoglycaemia associated with the use of inhibitors of angiotensinconverting enzyme. Lancet 1996;345:1195–1198.

154. Morris AD, Boyle DIR, McMahon AD et al. ACE inhibitor use is associated with hospitalization for severe hypoglycaemia in patients with diabetes. Diabetes Care 1997;20:1363–1379.

155. Dickstein K, Kjekshus J; the OPTIMAAL Steering Committee, for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and mor￾bidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002;360:752–760.

156. Pfeffer MA, McMurray JJ, Velazques EJ et al. for the Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349: 1893–1906.

157. Granger CB, McMurray JJV, Yusuf S et al. for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative Trial. Lancet 2003;362: 772–776.

158. Opie LH, Thomas M. Propranolol and experimental myocardial infarction: substrate effects. Postgrad Med J 1976;52(Suppl. 4):124–133.

159. Da´vila￾Roma´n VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2002;40:271–277.

160. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 1999;353: 9–13.

161. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J et al. for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Fail￾ure (MERIT-HF). JAMA 2000;283:1295–1302.

162. Deedwania PC, Giles TD, Klibaner M, Ghali JK, Herlitz J, Hildebrandt P, Kjekshus J, Spinar J, Vitovec J, Stanbrook H, Wikstrand J; MERIT-HF Study Group. Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J 2005;149:159–167.

163. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P et al. for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651–1658.

164. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. for the COMET Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7–13.

165. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther 1995;57: 601–609.

166. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. for the Randomized Aldactone Evaluation Study Investigators. The effects of spironolactone on morbidity and mortality in patients with severe heart fail￾ure. N Engl J Med 1999;341: 709–717.

167. Parsonage WA, Hetmanski D, Cowley AJ. Beneficial haemodynamic effects of insulin in chronic heart failure. Heart 2001;85:508–513.

168. McNulty PH, Pfau S, Deckelbaum LI. Effect of plasma insulin level on myocardial blood flow and its mechanism of action. Am J Cardiol 2000;85: 161–165.

169. Smooke S, Horwich TB, Fonarow GC. Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 2005;149:168–174.

170. Khoury VK, Haluska B, Prins J, Marwick TH. Effects of glucose – insulinpotas￾sium infusion on chronic ischaemic left ventricular dysfunction. Heart 2003; 89: 61–65.

171. American Diabetes Association: Clinical Practice Recommendations 2004. Di￾abetes Care 2004;27(Suppl. 1):S5–S19.

172. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci 2000;99: 27–35.

173. Fragasso G, Piatti PM, Monti L, Palloshi A, Setola E, Puccetti P et al. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and is￾chemic cardiomyopathy. Am Heart J 2003;146:E18.

174. Thrainsdottir IS, von Bibra H, Malmberg K, Ryde´n L. Effects of trimetazidine on left ventricular function in patients with type 2 diabetes and heart failure. J Cardiovasc Pharmacol 2004;44: 101–108.

175. Lewis JF, DaCosta M, Wargowich T, Stacpoole P. Effects of dichloroacetate in patients with congestive heart failure. Clin Cardiol 1998;21: 888–889.

176. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22: 983–988.

177. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the An- Ticoagulation and Risk Factors in Atrial fibrillation (ATRIA) Study. JAMA 2001;285:2370–2375.

178. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Silent myocardial ischeamiaSi￾lent myocardial ischeamiath VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994;74:236–241.

179. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, White R, Furberg CD, Rautaharju PM. Incidence of and risk factors for atrial fibrillation in older adults. Circulation 1997;96: 2455–2461.

180. Levy S, Maarek M, Coumel P et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99: 3028–3035.

181. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Mani￾toba Follow-Up Study. Am J Med 1995;98:476–484.

182. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271: 840–844.

183. Flegel KM, Shipley MJ, Rose G. Risk of stroke in non-rheumatic atrial fibrillation. Lancet 1987;1:526–529.

184. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154: 1449–1457.

185. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987;147: 1561–1564.

186. Kuusisto J, Mykka¨nen L, Pyo¨ra¨la¨ K, Laakso M: Non-insulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994;25:1157–1164.

187. Davis TME, Millns H, Stratton IM, Holman RR, Turner RC, for the UK Prospective Diabetes Study Group. Risk factors for stroke in type 2 diabetes mellitus. United Kingdom Prospective Diabetes Study (UKPDS). Arch Intern Med 1999;159:1097–1103.

188. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-con￾trolled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen ATRIAL FIBRILLATIONASAK Study. Lancet 1989; 1:175–179.

189. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C, for the CA￾TRIAL FIBRILLATIONA Study Coinvestigators. Canadian Atrial fibrillation An￾ticoagulation (CATRIAL FIBRILLATIONA) Study. J Am Coll Cardiol 1991;18: 349–355.

190. The Boston Area Anticoagulation Trial for Atrial fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323: 1505–1511.

191. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke 1999; 30:1223–1229.

192. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406–1412.

193. The Stroke Prevention in Atrial fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. 1. Clinical features of patients at risk. Ann In￾tern Med 1992;116:1–5.

194. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, Halperin JL, for the Stroke prevention in atrial fibrillation investigators. Pathophysiologic correlates of thromboembolism in nonvavular atrial fibrillation: I. Reduced flow velocity in the left atrial appendage (the Stroke Prevention in Atrial fibrillation [SPATRIAL FIBRILLATION-III] Study). J Am Soc Echocardiogr 1999;12: 1080–1087.

195. Illien S, Maroto-Jarvinen S, von der Recke G, Hammerstingl C, Schmidt H, Kuntz-Hehner S, Luderitz B, Omran H. Atrial fibrillation: relation between clinical risk factors and transoesophageal echocardiographic risk factors for thromboembolism. Heart 2003;89: 165–168.

196. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501.

197. Albers GW, Dalen JE, Laupacis A et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194S–206S.

198. SPATRIAL FIBRILLATION Investigators. The Stroke Prevention in Atrial fibrillation III Study: rationale, design and patient features. J Stroke Cerebrovasc Dis 1997;5:341–353.

199. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of atrial fibrillation. JAMA 2001;285:2864–2870.

200. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290: 1049–1056.

201. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, Petersen P. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287–2292.

202. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2006;27: 1979–2030.

203. Singer DE, Albers GW, Dalen JA, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126;429–456.

204. Priori SG, Aliot E, Blomstrom-Lundqvist C, Bossaert L, Breithardt G, Brugada P, Camm AJ, Cappato R, Cobbe SM, Di Mario C, Maron BJ, McKenna WJ, Pedersen AK, Ravens U, Schwartz PJ, Trusz-Gluza M, Vardas P, Wellens HJ, Zipes DP. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22: 1374–1450.

205. Kannel WB, Wilson PW, D’Agostino RB, Cobb J. Sudden coronary death in women. Am Heart J 1998;136:205–212.

206. Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, Stampfer MJ, Manson JE. Prospective study of sudden cardiac death among women in the United States. Circulation 2003;107: 2096–2101.

207. Curb JD, Rodriguez BL, Burchfiel CM, Abbott RD, Chiu D, Yano K. Related articles. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men. Circulation 1995;91: 2591–2595.

208. Balkau B, Jouven X, Ducimetiere P, Eschwege E. Diabetes as a risk factor for sudden death. Lancet 1999;354:1968–1969.

209. Jouven X, Lemaitre RN, Rea TD, Sotoodehnia N, Empana JP, Siscovick DS. Di￾abetes, glucose level, and risk of sudden cardiac death. Eur Heart J 2005;26:2142–2147.

210. Cosentino F, Egidy Assenza G. Diabetes and inflammation. Herz 2004; 29:749–759.

211. O’Brien IA, Mc Fadden JP, Corral RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991;79: 495–502.

212. Forsen A, Kangro M, Sterner G, Norrgren K, Thorsson O, Wollmer P, Sundkvist G. A 14-year prospective study of autonomic nerve function in Type 1 diabetic patients: association with nephropathy. Diabet Med 2004;21: 852–858.

213. Veglio M, Chinaglia A, Cavallo-Perin P. QT interval, cardiovascular risk factors and risk of death in diabetes. J Endocrinol Invest 2004; 27:175–181.

214. Rozanski GJ, Xu Z.A metabolic mechanism for cardiac Kþ channel remodelling. Clin Exp Pharmacol Physiol 2002;29:132–137.

215. Ewing DJ, Compbell IW, Clarke BF. The natural history of diabetic authonomic neuropathy. Q J Med 1980;49:95–108.

216. Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CD, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia 2000;43:561–570.

217. Ewing DJ, Boland O, Neilson JM et al. Autonomic neuropathy, QT interval lengthening and unexpected deaths in male diabetic patients. Diabetologia 1991;34:182–185.

218. Navarro X, Kennedy WR, Lowenson RB et al. Influence of pancreas transplantation on cardiorepiratory reflexes, nerve conduction and mortality in diabetes mellitus. Diabetes 1990;39:802–806.

219. Singh JP, Larson MG, O’Donnell CJ, Wilson PF, Tsuji H, Lloyd-Jones DM, Levy D. Association of hyperglycaemia with reduced heart rate variability (The Framingham Heart Study). Am J Cardiol 2000; 86:309–312.

220. Schroeder EB, Chambless LE, Liao D, Prineas RJ, Evans GW, Rosamond WD, Heiss G; Atherosclerosis Risk in Communities (ARIC) Study. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) Study. Diabetes Care 2005;28:668–674.

221. Suarez GA, Clark VM, Norell JE, Kottke TE, Callahan MJ, O’Brien PC, Low PA, Dyck PJ. Sudden cardiac death in diabetes mellitus: risk factors in the Rochester diabetic neuropathy study. J Neurol Neurosurg Psychiatry 2005;76:240–245.

222. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287: 2570–2581.

223. Meijer WT, Hoes AW, Rutgers D et al. Peripheral arterial disease in the elderly: the Rotterdam Study. Arterioscler Thromb Vasc Biol 1998; 18: 185–192.

224. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472–1479.

225. Jude EB, Oyibo SO, Chalmers N et al. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001;24:1433–1437.

226. Mozes G, Keresztury G, Kadar A, Magyar J, Sipos B, Dzsinich S, Gloviczki P. Atherosclerosis in amputated legs of patients with and without diabetes mellitus. Int Angiol 1998;17:282–286.

227. Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH: Medial arterial cal￾cification and its association with mortality and complications of diabetes. Diabetologia 1988;31:16–23.

228. Dormandy JA, Rutherford RB; TASC Working Group. TransAtlantic Inter- So￾ciety Concensus (TASC), Management of peripheral arterial disease (PAD). J Vasc Surg 2000;31:S1–S296.

229. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005;366:1725–1735.

230. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608–1621.

231. Hess H, Mietaschik A, Deichsel G. Drug induced inhibition of platelet function delays progression of peripheral occlusive arterial disease: a prospective double blind arteriographic controlled trial. Lancet 1985;1:416–419.

232. Caprie Steering Committee. A randomized, blinded, trial of clopidogrel ver￾sus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329–1339.

233. Kalani M, Apelqvist J, Blomback M et al. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive dis￾ease: a prospective, randomized, double-blind, placebocontrolled study. Diabetes Care 2003;26:2575–2580.

234. Loosemore T, Chalmers T, Dormandy J. A meta-analysis of randomized placebo control trials in Fontaine stages III and IV peripheral occlusive arterial disease. Int Angiol 1994;13:133–142.

235. Stegmayr B, Asplund K. Diabetes as a risk factor for stroke. A population per￾spective. Diabetologia 1995;38:1061–1068.

236. Mankovsky BN, Ziegler D. Stroke in patients with diabetes mellitus. Diabetes Metab Res Rev 2004;20:268–287.

237. Folsom AR, Rasmussen ML, Chambless ME et al. Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999;22:1077–1083.

238. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M, Roehm￾boldt ME, Palumbo PJ, Whisnant JP, Elveback LP. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-in￾sulin-dependent diabetic subjects. Stroke 1996;27:2033–2039.

239. Toyry JP, Niskanen LK, Lansimies EA, Partanen KP, Uusitupa MI. Autonomic neuropathy predicts the development of stroke in patients with non-insulindependent diabetes mellitus. Stroke 1996;27: 1316–1318.

240. Transient ischemic attack and stroke in a community-based diabetic cohort. Mayo Clin Proc 1983;58:56–58.

241. Laing SP, Swerdlow AJ, Carpenter LM, Slater SD, Burden AC, Botha JL, Morris AD, Waugh NR, Gatling W, Gale EA, Patterson CC, Qiao, Z, Keen, H. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke 2003;34: 418–421.

242. Johnston CS, Sidney S, Bernstein AL, Gress DR. A comparison of risk factors for recurrent TIA and stroke in patients diagnosed with TIA. Neurology 2003;28:280–285.

243. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033–1041.

244. Colwell JA. Aspirin therapy in diabetes (Technical review). Diabetes Care 1997;20:1767–1771.

245. Sivenius J, Laakso M, Piekkinen Sr, Smets P, Lowenthal A. European stroke prevention study: effectiveness of antiplatelet therapy in diabetic patients in secondary prevention of stroke. Stroke 1992;23:851–854.

246. Diener F, Coccheri S, Libretti A et al. European stroke prevention study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1–13.

247. Diener F, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, doubleblind, placebo-controlled trial. Lancet 2004,364: 331–337.

248. Bhatt DL, Fox KA, Hacke W et al. for the CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.

249. Rockson SG, Albers GW. Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Car￾diol 2004;43:929–935.

250. Imray CH, Tiivas CA. Are some strokes preventable? The potential role of tran￾scranial doppler in transient ischaemic attacks of carotid origin. Lancet Neu￾rol 2005;4:580–586.

251. Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke. A statement for health care professionals from the stroke council of the American Heart Association. Stroke 2001;32:280–293.

252. Tu JV, Wang H, Bowyer B, Green L, Fang J, Kucey D. Risk factors for death or stroke after carotid endarterectomy. Observations from the Ontario Carotid Endarterectomy Registry. Stroke 2003;34: 2568–2573.

253. Goodney PP, Schermehorn ML, Powell RJ. Current status of carotid artery stenting. J Vasc Surg 2006;43:406–411.

254. Wardlaw JM, delZoppo GJ, Yamaguchi T. Thrombolysis in acute ischemic stroke (Cochrane review). In: The Cochrane Library, Issue 2. Oxford Update Software 2002.

255. Sulter G, Elting JW, Langedijk M et al. Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a ran￾domized pilot study. Stroke 2003;34:101–104.

256. European Stroke Initiative Executive and Writing Committee. The European stroke initiative recommendations for stroke management: update 2003. Cerebrovasc Dis 2003;314:1303–1306.

257. Thorell A, Nygren J, Ljungqvist O. Insulin resistance: a marker of surgical stress. Curr Opin Clin Nutr Metab Care 1999;21:69–78.

258. McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycaemia. Crit Care Clin 2001;17:107–124.

259. Hill M, McCallum R. Altered transcriptional regulation of phosphoenolpyruvate carboxykinase in rats following endotoxin treatment. J Clin Invest 1991;88:811–816.

260. Khani S, Tayek JA. Cortisol increases gluconeogenesis in humans: its role in the metabolic syndrome. Clin Sci (Lond.) 2001;101: 739–747.

261. Watt MJ, Howlett KF, Febbraio MA et al. Adrenalin increases skeletal muscle glycogenolysis, pyruvate dehydrogenase activation and carbohydrate oxidation during moderate exercise in humans. J Physiol 2001;534:269–278.

262. Flores EA, Istfan N, Pomposelli JJ et al. Effect of interleukin-1 and tumor necrosis factor/cachectin on glucose turnover in the rat. Metabolism 1990;39: 738–743.

263. Sakurai Y, Zhang XJ, Wolfe RR. TNF directly stimulates glucose uptake and leucine oxidation and inhibits FFA flux in conscious dogs. Am J Physiol 1996;270:E864–E872.

264. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 1992;130:43–52.

265. Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355: 773–778.

266. Muhlestein JB, Anderson JL, Horne BD et al. Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 2003;146:351–358.

267. Suematsu Y, Sato H, Ohtsuka T et al. Predictive risk factors for delayed extubation in patients undergoing coronary artery bypass grafting. Heart Vessels 2000;15:214–220.

268. Krinsley JS. Association between hyperglycaemia and increased hospital mor￾tality in a heterogeneous population of critically ill patients. Mayo Clin Proc 2003;78:1471–1478.

269. Faustino EV, Apkon M. Persistent hyperglycaemia in critically ill children. J Pe￾diatr 2005;146:30–34.

270. Capes SE, Hunt D, Malmberg K et al. Stress hyperglycaemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke 2001;32:2426–2432.

271. Rovlias A, Kotsou S. The influence of hyperglycaemia on neurological outcome in patients with severe head injury. Neurosurgery 2000;46:335–342.

272. Jeremitsky E, Omert LA, Dunham M et al. The impact of hyperglycaemia on patients with severe brain injury. J Trauma 2005;58: 47–50.

273. Yendamuri S, Fulda GJ, Tinkoff GH. Admission hyperglycaemia as a prognos￾tic indicator in trauma. J Trauma 2003;55:33–38.

274. Laird AM, Miller PR, Kilgo PD et al. Relationship of early hyperglycaemia to mortality in trauma patients. J Trauma 2004;56: 1058–1062.

275. Gore DC, Chinkes D, Heggers J et al. Association of hyperglycaemia with in￾creased mortality after severe burn injury. J Trauma 2001;51: 540–544.

276. Ingels C, Debaveye Y, Milants I, Buelens E, Peeraer A, Devriendt Y, Vanhoutte T, Van Damme A, Schetz M, Wouters PJ, Van den Berghe G. Strict blood glucose control with insulin during intensive care after cardiac surgery: impact on 4-years survival, dependency on medical care, and quality-of-life. Eur Heart J 2006;27:2716–2724.

277. Van den Berghe G, Schoonheydt K, Becx P et al. Insulin therapy protects the central and peripheral nervous system of intensive care patients. Neurology 2005;64:1348–1353.

278. Van den Berghe G, Wilmer A, Hermans G et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449–461.

279. Krinsley JS. Effect of an intensive glucose management protocol on the mor￾tality of critically ill adult patients. Mayo Clin Proc 2004;79: 992–1000.

280. Grey NJ, Perdrizet GA. Reduction of nosocomial infections in the surgical intensive-care unit by strict glycaemic control. Endocr Pract 2004;10(Suppl. 2):46–52.

281. Furnary AP, Wu Y, Bookin SO. Effect of hyperglycaemia and continuous intravenous insulin infusions on outcomes of cardiac surgical procedures: the Port￾land Diabetic Project. Endocr Pract 2004;10 (Suppl. 2):21–33.

282. Chaney MA, Nikolov MP, Blakeman BP, Bakhos M. Attempting to maintain normoglycaemia during cardiopulmonary bypass with insulin may initiate postoperative hypoglycaemia. Anesth Analg 1999;89: 1091–1095.

283. Carvalho G, Moore A, Qizilbash B et al. Maintenance of normoglycaemia during cardiac surgery. Anesth Analg 2004;99:319–324.

284. Van den Berghe G, Wouters PJ, Bouillon R et al. Outcome benefit of intensive insulin therapy in the critically ill: insulin dose versus glycaemic control. Crit Care Med 2003;31:359–366.

285. Finney SJ, Zekveld C, Elia A et al. Glucose control and mortality in critically ill patients. JAMA 2003;290:2041–2047.

286. Klip A, Tsakiridis T, Marette A, Ortiz PA. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. FASEB J 1994;8:43–53.

287. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004;114:1187–1195.

288. Vanhorebeek I, De Vos R, Mesotten D et al. Strict blood glucose control with insulin in critically ill patients protects hepatocytic mitochondrial ultrastructure and function. Lancet 2005;365:53–59.

289. Langouche L, Vanhorebeek I, Vlasselaers D et al. Intensive insulin therapy pro￾tects the endothelium of critically ill patients. J Clin Invest 2005;115: 2277–2286.

290. Weekers F, Giuletti A-P, Michalaki M et al. Endocrine and immune effects of stress hyperglycaemia in a rabbit model of prolonged critical illness. Endocrinology 2003;144:5329–5338.

291. Mesotten D, Swinnen JV, Vanderhoydonc F et al. Contribution of circulating lipids to the improved outcome of critical illness by glycaemic control with intensive insulin therapy. J Clin Endocrinol Metab 2004;89:219–226

292. Hansen TK, Thiel S, Wouters PJ et al. Intensive insulin therapy exerts anti-in￾flammatory effects in critically ill patients, as indicated by circulating mannose-binding lectin and C-reactive protein levels. J Clin Endocrinol Metab 2003;88:1082–1088.

293. Das UN. Insulin: an endogenous cardioprotector. Curr Opin Crit Care 2003;9:375–383.

294. Jonassen A, Aasum E, Riemersma R et al. Glucose-insulin-potassium reduces infarct size when administered during reperfusion. Cardiovasc Drugs Ther 2000;14:615–623.

295. Gao F, Gao E, Yue T et al. Nitric oxide mediates the antiapoptotic effect of insulin in myocardial ischaemia-reperfusion: the role of PI3-kinase, Akt and eNOS phosphorylation. Circulation 2002;105: 1497–1502.

296. Jonassen A, Sack M, Mjos O, Yellon D. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signalling. Circ Res 2001;89: 1191–1198.

297. Bothe W, Olschewski M, Beyersdorf F, Doenst T. Glucose-insulinpotassium in cardiac surgery: a meta-analysis. Ann Thorac Surg 2004;78:1650–1657.

298. Pagano E, Brunetti M, Tediosi F et al. Costs of diabetes. A methodological analysis of the literature. Pharmacoeconomics 1999;15: 583–595.

299. Songer TJ. The economic costs of NIDDM. Diabetes Metab Rev 1992;8: 389–404.

300. American Diabetes Association. Direct and indirect costs of diabetes in the United States in 1987. Alexandria, VA: ADA; 1987.

301. American Diabetes Association. Standards of medical care for patients with di￾abetes mellitus. American Diabetes Association. Diabetes Care 1994;17: 616–623.

302. American Diabetes Association. Economic consequences of diabetes mellitus in the U.S. in 1997. American Diabetes Association. Diabetes Care 1998;21: 296–309.

303. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932.

304. Huse DM, Oster G, Killen AR et al. The economic costs of non-insulin-dependent diabetes mellitus. JAMA 1989;262:2708–2713.

305. Kegler MC, Lengerich EJ, Norman M et al. The burden of diabetes in North Carolina. N C Med J 1995;56:141–144.

306. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes mellitus, 1992. J Clin Endocrinol Metab 1994;78:809A–809F.

307. Warner DC, McCandless RR, De Nino LA et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996;19:1416–1419.

308. Barcelo A, Aedo C, Rajpathak S et al. The cost of diabetes in Latin America and the Caribbean. Bull World Health Organ 2003;81: 19–27.

309. Chale SS, Swai AB, Mujinja PG et al. Must diabetes be a fatal disease in Africa? Study of costs of treatment. BMJ 1992;304:1215–1218.

310. Dawson KG, Gomes D, Gerstein H et al. The economic cost of diabetes in Canada, 1998. Diabetes Care 2002;25:1303–1307.

311. Lin T, Chou P, Lai MS et al. Direct costs-of-illness of patients with diabetes mellitus in Taiwan. Diabetes Res Clin Pract 2001; 54(Suppl. 1):S43–S46.

312. McKendry JB. Direct costs of diabetes care: a survey in Ottawa, Ontario 1986. Can J Public Health 1989;80:124–128.

313. Phillips M, Salmeron J. Diabetes in Mexico—a serious and growing problem. World Health Stat Q 1992;45:338–346.

314. Gerard K, Donaldson C, Maynard AK. The cost of diabetes. Diabet Med 1989;6:164–170.

315. Gray A, Fenn P, McGuire A. The cost of insulin-dependent diabetes mellitus (IDDM) in England and Wales. Diabet Med 1995;12: 1068–1076.

316. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. J Intern Med 1998;244:461–468.

317. Henriksson F, Agardh CD, Berne C et al. Direct medical costs for patients with type 2 diabetes in Sweden. J Intern Med 2000;248: 387–396.

318. Jonsson B. Diabetes—the cost of illness and the cost of control. An estimate for Sweden 1978. Acta Med Scand Suppl 1983;671: 19–27.

319. Kangas T, Aro S, Koivisto VA et al. Structure and costs of health care of diabetic patients in Finland. Diabetes Care 1996;19:494–497.

320. Lucioni C, Garancini MP, Massi-Benedetti M et al. The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003;2:121–133.

321. Oliva J, Lobo F, Molina B et al. Direct health care costs of diabetic patients in Spain. Diabetes Care 2004;27:2616–2621.

322. Spri, Diabetesva°rden i va°gska°len. Yngre och medela°lders diabetiker rapporterar om va°rdutnyttjande, ekonomi och kvalitet. Spri rapport 451. ISSN 0586–1691. 1997, Spri: Stockholm.

323. Triomphe A, Flori YA, Costagliola D et al. The cost of diabetes in France. Health Policy 1988;9:39–48.

324. Jonsson B. Health economic aspects of diabetes. Endocrinol Metab 1997;4(Suppl. B):135–137.

325. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002;45:S5–S12.

326. Williams R, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia 2002;45: S13–S17. 708. Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 1999;42:1293–1301.

327. Mihaylova B, Briggs A, Armitage J et al. Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomized trial in 20,536 individuals. Lancet 2005; 365:1779–1785.

328. Clarke PM, Gray AM, Briggs A et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868–877.

329. Casciano J, Doyle J, Casciano R et al. The cost-effectiveness of doxazosin for the treatment of hypertension in type II diabetic patients in the UK and Italy. Int J Clin Pract 2001;55:84–92.


For citation:


Ryden L., Standl E., Bartnik M., Van den Berghe G., Betteridge J., de Boer M., Cosentino F., Jonsson B., Laakso M., Malmberg K., Priori S., Ostergren J., Tuomilehto J., Thrainsdottir I. GUIDELINES ON DIABETES, PRE-DIABETES, AND CARDIOVASCULAR DISEASES. Rational Pharmacotherapy in Cardiology. 2007;3(5):88-111. (In Russ.) https://doi.org/10.20996/1819-6446-2007-3-5-88-111

Views: 2031


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)